Mr. Blair McInnis reports

SPECTRAL MEDICAL INC. ANNOUNCES DIRECTOR RESIGNATION

Jim Funk has tendered his resignation from the board of directors of Spectral Medical Inc., such resignation to take effect immediately. Mr. Funk has served as a member of the board of directors since June 20, 2022.

The board of directors has initiated a board search process to augment expertise and counsel relative to regulatory and clinical trials. The company anticipates having a new director to replace Mr. Funk in the near future.

About Spectral Medical Inc.

Spectral is a phase 3 company seeking U.S. Food and Drug Administration (FDA) approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the company's endotoxin activity assay (EAA), the only FDA-cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. In March, 2009, Spectral obtained the exclusive development and commercial rights in the United States for PMX, and, in November, 2010, it signed an exclusive distribution agreement for this product in Canada. In July, 2022, the U.S. FDA granted breakthrough device designation for PMX for the treatment of endotoxemic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT.

We seek Safe Harbor.